| pubmed-article:1623558 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1623558 | lifeskim:mentions | umls-concept:C0012655 | lld:lifeskim |
| pubmed-article:1623558 | lifeskim:mentions | umls-concept:C0003340 | lld:lifeskim |
| pubmed-article:1623558 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1623558 | lifeskim:mentions | umls-concept:C1704410 | lld:lifeskim |
| pubmed-article:1623558 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:1623558 | pubmed:dateCreated | 1992-8-7 | lld:pubmed |
| pubmed-article:1623558 | pubmed:abstractText | The effects of priming on the susceptibility of B-cell subsets to tolerance induction have been tested in a model system in which anti-immunoglobulin (anti-Ig) has been employed as a surrogate for tolerogen. T-cell-depleted B cells were primed in vitro with fluorescein or trinitrophenylated Ficoll (a thymus-independent (TI) antigen) and then exposed overnight to anti-Ig to attempt to induce B-cell anergy. Primed cells were relatively resistant to this tolerance protocol and resistance was hapten specific. The dose response and kinetics suggested that this process was not due to receptor blockade or modulation, but was an active process. Moreover, this priming for resistance to tolerance was reproduced in vivo upon intraperitoneal treatment with haptenated Ficoll. Such in vivo priming for tolerance resistance was long-lasting and did not occur with a thymus-dependent priming protocol with fluoresceinated hemocyanin. These results are discussed in terms of TI priming to drive B cells into cycle and express novel functional and phenotypic properties. | lld:pubmed |
| pubmed-article:1623558 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1623558 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1623558 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1623558 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1623558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1623558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1623558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1623558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1623558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1623558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1623558 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1623558 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:1623558 | pubmed:issn | 0008-8749 | lld:pubmed |
| pubmed-article:1623558 | pubmed:author | pubmed-author:ScottD WDW | lld:pubmed |
| pubmed-article:1623558 | pubmed:author | pubmed-author:YaoX RXR | lld:pubmed |
| pubmed-article:1623558 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1623558 | pubmed:volume | 142 | lld:pubmed |
| pubmed-article:1623558 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1623558 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1623558 | pubmed:pagination | 434-43 | lld:pubmed |
| pubmed-article:1623558 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:1623558 | pubmed:meshHeading | pubmed-meshheading:1623558-... | lld:pubmed |
| pubmed-article:1623558 | pubmed:meshHeading | pubmed-meshheading:1623558-... | lld:pubmed |
| pubmed-article:1623558 | pubmed:meshHeading | pubmed-meshheading:1623558-... | lld:pubmed |
| pubmed-article:1623558 | pubmed:meshHeading | pubmed-meshheading:1623558-... | lld:pubmed |
| pubmed-article:1623558 | pubmed:meshHeading | pubmed-meshheading:1623558-... | lld:pubmed |
| pubmed-article:1623558 | pubmed:meshHeading | pubmed-meshheading:1623558-... | lld:pubmed |
| pubmed-article:1623558 | pubmed:meshHeading | pubmed-meshheading:1623558-... | lld:pubmed |
| pubmed-article:1623558 | pubmed:meshHeading | pubmed-meshheading:1623558-... | lld:pubmed |
| pubmed-article:1623558 | pubmed:meshHeading | pubmed-meshheading:1623558-... | lld:pubmed |
| pubmed-article:1623558 | pubmed:meshHeading | pubmed-meshheading:1623558-... | lld:pubmed |
| pubmed-article:1623558 | pubmed:meshHeading | pubmed-meshheading:1623558-... | lld:pubmed |
| pubmed-article:1623558 | pubmed:meshHeading | pubmed-meshheading:1623558-... | lld:pubmed |
| pubmed-article:1623558 | pubmed:meshHeading | pubmed-meshheading:1623558-... | lld:pubmed |
| pubmed-article:1623558 | pubmed:meshHeading | pubmed-meshheading:1623558-... | lld:pubmed |
| pubmed-article:1623558 | pubmed:meshHeading | pubmed-meshheading:1623558-... | lld:pubmed |
| pubmed-article:1623558 | pubmed:meshHeading | pubmed-meshheading:1623558-... | lld:pubmed |
| pubmed-article:1623558 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1623558 | pubmed:articleTitle | Effect of priming with a thymus-independent antigen on susceptibility to B-cell tolerance. | lld:pubmed |
| pubmed-article:1623558 | pubmed:affiliation | Division of Immunology and Immunotherapy, University of Rochester Cancer Center, New York. | lld:pubmed |
| pubmed-article:1623558 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1623558 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:1623558 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:1623558 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:1623558 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
